AzTrials
AzTrials

Lung CancerNCT07564960

Social Optimization Study

A study testing Social support receptivity training and Social awareness training in people with Lung Cancer, run by University of Arizona at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study tests whether clinical interventions to optimize support receptivity lead to improvements in social integration and quality of life (QOL) amongst long-term lung cancer survivors. The feasibility and acceptability of the intervention and assessment procedures will be examined. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Lung Cancer
What is being tested?
Social support receptivity training and Social awareness training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
27 Apr 2026to 31 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults (18 Years or Older)
  • History of lung cancer
  • at least 12 months since cancer diagnosis
  • fluent in English
  • able to attend virtually or in person sessions at the University of Arizona.

Who cannot join

  • Less than 12 months of cancer diagnosis at time of enrollment
  • undergoing treatment for mood or anxiety health issues at time of enrollment
  • unable to provide informed consent.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Francis Morales-Lozada contact

(520) 621-0563

fmoraleslozada@arizona.edu

United States1 site, 1 recruiting
  • University of Arizona Mel and Enid Zuckerman College of Public Health

    Tucson, Arizona, 85719

    Francis Morales-Lozada, 520-621-0563, fmoraleslozada@arizona.edu

    Scott Carvajal, PhD, MPH

    Recruiting

Other trials in United States

About this study

Official title: Improving the Lives of Cancer Survivors Through Enhancing Support Receptivity

This study tests whether clinical interventions to optimize support receptivity lead to improvements in social integration and quality of life (QOL) amongst long-term lung cancer survivors. The feasibility and acceptability of the intervention and assessment procedures will be examined. Thirty long-term lung cancer survivors will be randomized to a support receptivity intervention or an attention-control condition. Our intervention draws on cognitive behavioral therapy (CBT) strategies to reduce social anxiety, improve social awareness, and promote social integration. We will use two novel in vivo sampling methods using a mobile phone platform to assess social engagement and QOL improvements: 1) recording via the Electronically Activated Recorder to capture daily social interactions, and 2) repeated self-report sampling where participants answer questions about their social engagement experiences via their personal cell phone.

Read the detailed description

The growing cancer survivorship population. This year, more than 1.77 million Americans will receive a life-altering cancer diagnosis. Fortunately, improvements in early detection and care have led to dramatic increases in survival. Over 18 million Americans or 5.4% of the total U.S. population now identify as cancer survivors with an expected growth to 26 million by 2040. Recognition of these immense changes in survival has led the National Cancer Institute (NCI) to found the Office of Cancer Survivorship (OCS) with a stated goal of "enhancing the quality and length of survival of all persons diagnosed with cancer…" Consistent with its mission, NCI/OCS is prioritizing research that improves the QOL of this growing survivorship population.

Social integration is a critical moderator. Social integration is one potential resilience factor that may be key to improving QOL among cancer survivors. Social integration, the degree of social embeddedness and strength of social ties, is amongst the most robust predictors of a broad range of mental and physical health outcomes. Robust, replicated research documents that people who are more socially integrated experience lower rates of depression, anxiety, and most forms of chronic illness and experience lower age-adjusted disease-specific and all-cause mortality. Decades of research show that interventions to provide more support including via support groups, community events, or provision of supportive persons can improve mental and physical health outcomes. At the same time, the improvements in these outcomes are modest, suggesting that not all relevant factors are accounted for.

Work from our team examining Hispanic advantages in mental and physical health via culturally moderated social integration suggest that support receptivity is a key element of social integration effectiveness. This revelation suggests that social integration is an interactive process not unlike effective neuronal communication. Neuron communication is moderated by both the adequacy of the signal and the sensitivity of the receptor. Both must be effective for transmission to take place. Social integration benefits may work the same way. While nearly all social integration interventions have focused on providing sufficient support, almost no interventions have sought to enhance support receptivity to enhance social integration effects in the context of physical health such as cancer survivorship.

The current goal is to test whether clinical interventions to optimize support receptivity lead to improvements in social integration and QOL amongst cancer survivor populations. A pilot randomized clinical trial is proposed to evaluate feasibility and acceptability of the intervention and assessment procedures, and to explore whether the intervention can improve QOL through optimizing survivors' social receptivity to determine proof-of-concept. We propose to enroll 30 long-term (> 12 months post-treatment) lung cancer survivors randomized to either a support receptivity intervention or attention-control condition. Our intervention draws on the large body of cognitive behavioral therapy (CBT) interventions to reduce social anxiety, improve social awareness, and promote social integration for a wide range of mental health conditions. The proposed 3-week, 6 session CBT intervention specifically targets cognitive awareness of prosocial cues coupled with Behavioral Activation and Social Skills Training to improve target person social engagement. Building on our ongoing, NCI-funded work on social engagement in lung cancer patients, we will use two novel in vivo sampling methods using a mobile phone platform to assess social engagement and QOL improvements: 1) recording via the Electronically Activated Recorder (EAR)17 to capture frequency of daily social interactions, and 2) repeated self-report sampling (ecological momentary assessments) where participants will be prompted to answer questions about their social engagement experiences via their personal cell phone.

The following aims are proposed:

Aim 1: Explore whether a CBT intervention targeting social receptivity can improve QOL in cancer survivors compared to an attention control condition to determine proof-of-concept. Hypothesis: We expect that the intervention will produce improvements via the targeted mechanism with sustained differences at 2 months post.

Aim 2: Explore the degree to which the CBT intervention increases objectively assessed social engagement as a putative mechanism. Hypothesis: We expect to demonstrate proof-of-concept that social engagement is malleable with implications for survivor mental and social health in alignment with NCI survivorship priorities.

Conditions
Lung Cancer
Being tested
Social support receptivity training, Social awareness training
Keywords
Social support, Psycho-oncology, Lung neoplasms
Medical subject headings
Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Social support receptivity trainingBehavioural

    A 3-week, 6-session CBT intervention that targets cognitive awareness of prosocial cues and leverages behavioral activation and social skills training

  • Social awareness trainingBehavioural

    A 3-week, 6 session program designed to increase awareness of available social support.

Study groups in NCT07564960
Study groupRoleWhat they receive
Social support receptivity trainingExperimentalParticipants will receive a 3-week, 6 session CBT intervention targeting cognitive awareness of prosocial cues coupled with behavioral activation and social skills training to improve target person social engagement.
Receives: Behavioral: Social support receptivity training
Social awareness trainingActive comparatorParticipants receiving a 3-week, 6 session program designed to increase awareness of the social support already available to them.
Receives: Behavioral: Social awareness training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility assessed by recruitment and retention rates

    Given the pilot nature of this work, the intervention/study will be deemed feasible if 20% of eligible potential participants approached enroll and 50% of enrolled participants are retained at post-intervention

    Measured: Throughout the recruitment period

  2. Acceptability assessed by study-specific survey after the intervention

    The intervention/study will be deemed acceptable if, on average, participants report satisfaction with the overall program/study as ≥2 on a 0-4 scale.

    Measured: 3 weeks - immediately after the intervention

Secondary outcomes (6)
  1. Change in quality of life (QOL) using the SF-36 from baseline to immediately after the intervention.

    Participants will complete the 36-item SF-36, which evaluates eight health domains-physical functioning, pain, vitality, social functioning, and mental health-covering physical and mental components. Scores on each domain range from 0-100, with higher scores indicating better quality of life (QOL).

    Measured: 3 weeks - immediately after the intervention

  2. Change in Perceived Stress using the Perceived Stress Scale (PSS) from baseline to immediately after the intervention

    Participants will complete a 10-item PSS, which evaluates an individual's stress level. Scores range from 0-40, with higher scores indicating higher perceived stress.

    Measured: 3 weeks - immediately after the intervention

  3. Change in depression using the CES-D scale from baseline to immediately after the intervention

    Participants will complete a 10-item CES-D, which evaluates an individual's self-reported symptoms of depression. The total score is calculated by totaling all items scored after reversing the positive mood items. Possible range for scores is 0-11 with higher scores representing greater degrees of depressed mood.

    Measured: 3 weeks - immediately after the intervention

  4. Change in network diversity using the Berkman-Syme Social Network Index (BS-SNI) from baseline to immediately after the intervention

    Participants will complete the BS-SNI, which assesses network diversity, and the number of people in an individual's network.

    Measured: 3 weeks - immediately after the intervention

  5. Change in subject loneliness and social isolation using the UCLA-Loneliness Scale from baseline to immediately after the intervention

    Participants will complete the 10-item UCLA Loneliness Scale, which measures subjective loneliness and social isolation. Higher scores represent higher levels of loneliness.

    Measured: 3 weeks - immediately after the intervention

  6. Change in Multidimensional Scale of Perceived Social Support (MSPSS) scores from baseline to immediately after the intervention

    Participants will complete a 12-item MSPSS, which measures an individual's perception of support. A sum through all scores can range from 12-84, with higher scores noting a higher perceived support.

    Measured: 3 weeks - immediately after the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2026
  2. Study start27 Apr 2026
  3. Primary completion31 Oct 2026 (estimated)
  4. Study completion31 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07564960
Sponsor's protocol ID
STUDY00007008
Status last verified
Sep 2026
First submitted
27 Apr 2026
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Social support receptivity training and Social awareness training in people with Lung Cancer, run by University of Arizona at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Francis Morales-Lozada ((520) 621-0563, fmoraleslozada@arizona.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility assessed by recruitment and retention rates (time frame: Throughout the recruitment period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in